Chronic kidney disease (CKD) and type 2 diabetes are two serious and sometimes silent conditions that are often linked. Type 2 diabetes can lead to CKD and is a leading cause of end-stage kidney disease (ESKD). 

Since these conditions often go hand-in-hand, scientists have created a medication specifically to treat CKD in those with type 2 diabetes. Learn more about Finerenone (Kerendia, Bayer), an FDA-approved medication used to reduce the risk of decreased estimated glomerular filtration rate (eGFR), kidney failure, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure.* 

What is Finerenone?

Finerenone is a first-in-class nonsteroidal mineralocorticoid receptor antagonist designed to treat CKD associated with type 2 diabetes. It received FDA approval after the phase 3 FIDELIO-DKD trial study, which demonstrated positive kidney and cardiovascular outcomes in patients with CKD associated with type 2 diabetes. 

Why Is It Important? 

“Chronic kidney disease associated with type 2 diabetes can have such a debilitating impact on patients’ lives. Unfortunately, this disease is far-reaching, as up to 40% of all patients with type 2 diabetes develop chronic kidney disease,” said kidney transplant patient and National Kidney Foundation CEO Kevin Longino in a press release. “It is important for physicians and patients to have new treatment options that can slow chronic kidney disease progression.”

How Does Finerenone work?

Finerenone blocks the overaction of the mineralocorticoid receptor, which is thought to cause fibrosis and inflammation. Fibrosis and inflammation can often lead to permanent kidney damage. 

Is It Available?

As of July 2021, Finerenone is scheduled for release in the United States at the end of this month. If you are interested in taking Finerenone, speak to your nephrologist or primary care physician to see if you are a good candidate. 

*Hippensteele, A. (2021, July 20). Finerenone Receives FDA Approval for Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes. Pharmacy Times. https://www.pharmacytimes.com/view/finerenone-receives-fda-approval-for-treatment-of-chronic-kidney-disease-associated-with-type-2-diabetes